Bank Of America Corp Vectiv Bio Holding Ag Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 Aug 14, 2023	BUY	$8.29 - $16.97 $6.27 Million - $12.8 Million	756,536 Added 1903.67%	796,277 $13.4 Million
Q1 2023 May 12, 2023	BUY	$7.34 - $9.15 $259,491 - $323,479	35,353 Added 805.67%	39,741 $338,000
Q4 2022 Feb 10, 2023	BUY	$7.79 - $8.98 $17,036 - $19,639	2,187 Added 99.36%	4,388 $38,000
Q3 2022 Nov 14, 2022	BUY	$4.7 - $6.07 $10,340 - $13,354	2,200 Added 220000.0%	2,201 $13,000
Q2 2022 Aug 12, 2022	SELL	$4.2 - $6.55 $359,028 - $559,913	-85,483 Reduced 100.0%	1 $0
Q1 2022 May 16, 2022	BUY	$4.6 - $5.8 $58,889 - $74,251	12,802 Added 17.61%	85,484 $403,000
Q4 2021 Feb 08, 2022	BUY	$2.83 - $7.26 $203,774 - $522,756	72,005 Added 10635.89%	72,682 $357,000
Q3 2021 Nov 15, 2021	BUY	$6.7 - $11.54 $4,529 - $7,801	676 Added 67600.0%	677 $5,000
Q2 2021 Sep 13, 2021	BUY	$11.66 - $24.23 $11 - $24	1 New	1 $0

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.